Clinical trials: Symptomatic Ischemic Heart Disease
Coronary Arterioscleroses
EucaLimus Post-Market Registry
To collect post marketing surveillance data on consecutive patients with coronary heart disease intended to be or treated by the Eucalimus sirolimus eluting PTCA stent when used according to the Instructions for Use.
- Trial name
- NCT06621524
- Testing
- EucaLimus coronary stent system
- Where
- 10 sites in Czechia, Malaysia and 1 more
- Volunteers
- 251 people
- Sponsor
- OrbusNeich
Stable Angina
Stable Angina Observational Registry
The purpose of this study is to describe the clinical profile and current status of the diagnosis and management of stable angina in India by non-interventional consulting physicians (CP) through a large multicenter observational…
- Trial name
- STAR (NCT01552109)
- Where
- India
- Volunteers
- 2,079 people
- Sponsor
- Medtronic Vascular
Symptomatic Ischemic Heart Disease
CoStar Catheter System Evaluation
To evaluate product performance and safety of the Catheter Design for the treatment of a single coronary lesion.
- Trial name
- CONCISE (NCT00993785)
- Testing
- Costar Coronary Stent Delivery System
- Where
- Germany
- Volunteers
- 58 people
- Sponsor
- Conor Medsystems
Cerebral Stroke, Thrombosis, Deep Vein
A Study of Adverse Events and Suspected Adverse Drug Reactions in Patients Under Apixaban for Prevention of Stroke and Systemic Embolism With Non-Valvular Atrial Fibrillation and Venous Thromboembolic Events in Patients Who Have Undergone Elective Hip or Knee Replacement Surgery
To characterize and analyze the number, type and incidence of adverse events/suspected adverse drug reactions in patients treated with Apixaban, according to therapeutic indications approved in Mexico.
- Conditions
- Cerebral Stroke, Thrombosis, Deep Vein, Pulmonary Embolism
- Trial name
- NCT03804125
- Sponsor
- Pfizer
Hypertrophic Cardiomyopathy
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
The primary objective of this study was to evaluate the effect of eleclazine (GS-6615) on exercise capacity as measured by Peak oxygen uptake (VO2) achieved during cardiopulmonary exercise testing (CPET), in participants with…
- Trial name
- LIBERTY-HCM (NCT02291237)
- Testing
- Eleclazine
- Where
- 46 sites in United States, Australia and 6 more
- Volunteers
- 172 people
- Sponsor
- Gilead Sciences
Coronary Artery Disease
Advanced NanoTherapies Dual-API DCB to Treat De-Novo Lesions in Patients With Symptomatic Coronary Artery Disease
This prospective, single-arm, multi-center, safety and feasibility first-in-human study will evaluate the safety and feasibility of the SirPlux Duo™ Dual-API Coated PTCA Balloon Catheter to treat de-novo lesions between ≥2.0 and…
- Trial name
- ADVANCE-DCB (NCT05521542)
- Testing
- SirPlux Duo™ Dual-API Coated PTCA Balloon Catheter
- Where
- 5 sites in Australia, Dominican Republic and 1 more
- Volunteers
- 28 people
- Sponsor
- Advanced NanoTherapies
Angina
Ranolazine SR in Patients With Chronic Angina Who Remain Symptomatic Despite Maximal Treatment With Amlodipine
The study will be a multi-national, double-blind, randomized, placebo-controlled, parallel group study to evaluate the effectiveness of ranolazine (1000 mg twice daily) in approximately 500 patients with chronic angina who remain…
- Trial name
- NCT00091429
- Testing
- Ranolazine
- Volunteers
- 500 people
- Sponsor
- Gilead Sciences
Prevention of Atherothrombotic Events, Coronary Artery Disease (CAD)
Study to Learn More About the Safety and Effectiveness of Rivaroxaban (Xarelto) When Given Together With Acetylsalicylic Acid to Indian People With Narrowing of the Arteries of the Heart (CAD) and/or With Reduced Blood Flow in the Arteries of the Legs and Arms With Symptoms (Symptomatic PAD)
This is an observational study in which data from Indian people with coronary artery disease and / or symptomatic peripheral artery disease who will be receiving the drug rivaroxaban (Xarelto) are studied.
- Conditions
- Prevention of Atherothrombotic Events, Coronary Artery Disease (CAD), Symptomatic Peripheral Artery Disease (Symptomatic PAD)
- Trial name
- NCT04298567
- Testing
- Rivaroxaban (Xarelto,Bay 59-7939), Acetylsalicylic acid(ASA)
- Where
- India
- Volunteers
- 300 people
- Sponsor
- Bayer
Acute Coronary Syndrome, Myocardial Infarction
Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)
The purpose of the COGENT-1 clinical trial is to determine whether CGT-2168 (clopidogrel and omeprazole) compared to clopidogrel is safe and effective in reducing the incidence of gastrointestinal bleeding and symptomatic ulcer…
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
- Trial name
- COGENT-1 (NCT00557921)
- Testing
- CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin
- Where
- 491 sites in United States, Australia and 14 more
- Volunteers
- 5,000 people
- Sponsor
- Cogentus Pharmaceuticals
Ischemic Heart Disease
PIONIR Study (Presillion™ and Presillion™ Plus Stent Systems)
The purpose of this study is to collect and analyze additional information about the safety and effectiveness of the Presillion™ Stent System in the treatment of de novo stenotic lesions in native coronary arteries.
- Trial name
- NCT00840775
- Testing
- Catheterization, stent deployment
- Where
- 16 sites in Belgium, Germany and 2 more
- Volunteers
- 278 people
- Sponsor
- Medinol Ltd.
Angina Pectoris, Myocardial Ischemia
Self Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD)
VahatiCor's Coronary Sinus Reducer (A-FLUX) has been designed to improve angina or angina-like symptoms in patients with CMD. SERRA-I is an early feasibility study that evaluates the safety and clinical performance of the A-FLUX…
- Conditions
- Angina Pectoris, Myocardial Ischemia, Heart Diseases, Cardiovascular Diseases
- Trial name
- SERRA-I US (NCT07449325)
- Testing
- A-FLUX Reducer System
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- VahatiCor, Inc.
Angina (Stable), CAD - Coronary Artery Disease
Advanced NanoTherapies Dual-API DCB to Treat De-Novo and ISR Lesions in Patients With Symptomatic Coronary Artery Disease
The study objectives are: 1. To evaluate the safety and performance of the SirPlux Duo PTCA to treat coronary ISR lesions 2.00-4.00 mm (inclusive) in diameter in patients with symptomatic coronary artery disease. 2.
- Conditions
- Angina (Stable), CAD - Coronary Artery Disease, Unstable Angina, NSTEMI - Non-ST Segment Elevation MI
- Trial name
- ADVANCE-DUO (NCT07368933)
- Testing
- SirPlux Duo™ Dual API-Coated PTCA Balloon Catheter
- Where
- 3 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Advanced NanoTherapies
Ischemic Heart Disease
Evaluation of the Palmaz Mach-5 Grooved Bare Metal Coronary Stent System Versus the Palmaz Bare Metal Coronary Stent System in Patients With Symptomatic Ischemic Heart Disease: A Safety and Performance Study
This is a six (6) month, randomized, un-blinded, study to assess the safety and performance of the Palmaz Mach-5 Grooved Coronary Stent System vs. the Palmaz Bare Metal Coronary Stent System.
- Trial name
- NCT02759406
- Testing
- coronary stent
- Volunteers
- 48 people
- Sponsor
- Palmaz Scientific
Coronary Artery Disease (CAD)
Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABG
This is a 26-week (with a 26-week extension) multicenter, randomized, double-blind, placebo-controlled Phase 2 study of XC001 versus placebo.
- Trial name
- EXACT-CABG (NCT07118449)
- Testing
- XC001
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- XyloCor Therapeutics, Inc.
Coronary Microvascular Dysfunction, Coronary Microvascular Disease
Self-Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD) (SERRA-I Study)
VahatiCor's Coronary Sinus Reducer (A-FLUX) has been designed to improve angina or angina-like symptoms in patients with CMD. SERRA-I is an early feasibility study that evaluates the safety and clinical performance of the A-FLUX…
- Trial name
- NCT06991322
- Testing
- A-FLUX Reducer System
- Where
- 3 sites in Netherlands, Poland and 1 more
- Volunteers
- 30 people
- Sponsor
- VahatiCor, Inc.
Stable Angina
Effectiveness of a Combination of Trimetazidine With One Hemodynamic Agent in Patients Recently Diagnosed With Stable Angina and Still Symptomatic Despite First Line Hemodynamic Therapy
The purpose of this study is to assess in recently diagnosed stable Angina patients symptomatic despite first line hemodynamic therapy, the effect of a combination of this hemodynamic agent with a metabolic one (trimetazidine).
- Trial name
- NCT06298045
- Where
- Romania
- Volunteers
- 600 people
- Sponsor
- Servier Affaires Médicales
Coronary Artery Disease, Chest Pain
Coronary Obstruction Detection by Molecular Personalized Gene Expression (Corus CAD or ASGES)
To validate the use of Corus CAD (Age/Sex/Gene Expression score - ASGES) blood assay in subjects who are referred for the work-up of coronary artery disease.
- Conditions
- Coronary Artery Disease, Chest Pain, Cardiovascular Diseases, Coronary Heart Disease
- Trial name
- COMPASS (NCT01117506)
- Testing
- Corus CAD (ASGES)
- Where
- 7 sites in United States
- Volunteers
- 581 people
- Sponsor
- CardioDx
Coronary Artery Disease, Heart Disease, Ischemic
Artimes Pro Low Profile Dilatation Catheters for Pre-Dilatation in Patients With Symptomatic Ischemic Heart Disease
This is a prospective, non-randomized, open label, multi-center study including 60 patients with symptomatic ischemic heart disease with 70%-100% coronary artery stenoses and occlusions enrolled and treated in this…
- Conditions
- Coronary Artery Disease, Heart Disease, Ischemic, Coronary Stenosis
- Trial name
- NCT03301246
- Testing
- Artimes Pro Low Profile Dilatation Catheter
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Eminence Clinical Research, Inc.
de Novo, Symptomatic Ischemic Heart Disease
BIOFLOW-SV All Comers Registry
Assessment of the clinical safety and performance of the Orsiro drug-eluting stent in a real world setting in patients with small vessels with reference vessel diameter ≤2.75 mm.
- Conditions
- de Novo, Symptomatic Ischemic Heart Disease, Restenoses, Coronary
- Trial name
- BIOFLOW-SV (NCT03600948)
- Testing
- Orsiro Sirolimus Eluting Coronary Stent System
- Where
- 2 sites in Brazil
- Volunteers
- 261 people
- Sponsor
- Biotronik AG
Coronary Artery Disease
A Randomized Comparison of Personalized Therapy Mgmt Based On Coronary Atherosclerotic Plaque Vs. Usual Care for Symptomatic Patients With Suspicion of CAD
PARAMOUNT is a prospective randomized open-label trial testing the hypothesis that a personalized management strategy in symptomatic patients with suspicion of coronary artery disease (CAD), using a CT-based coronary…
- Trial name
- PARAMOUNT (NCT06713239)
- Testing
- Cleerly Labs and Cleerly ISCHEMIA
- Where
- 21 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Cleerly, Inc.